Article Details

Kinaset Therapeutics debuts with $40M for pan-JAK asthma med

Retrieved on: 2020-11-30 12:06:35

Tags for this article:

Click the tags to see associated articles and topics

Kinaset Therapeutics debuts with $40M for pan-JAK asthma med. View article details on hiswai:

Excerpt

The company starts out with $40 million from 5AM Ventures, <b>Atlas Venture</b> and Gimv that will push the program, KN-002, into the clinic next year.

Article found on: www.fiercebiotech.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo